BBLG
Bone Biologics Corporation
NASDAQ · Healthcare · Medical - Devices · US
$0.56
+0.39%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +48.6%
- EBIT
- +28.7%
- EPS
- +58.7%
- Free cash flow
- +20.6%
- Operating cash flow
- +20.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +80.1%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- +23.3%
- Net income
- +24.4%
- EPS
- +45.1%
- Free cash flow
- +34.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026